{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:03Z","timestamp":1787020743298,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019725","name":"Debra Austria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Wound management is a critical factor when treating patients with the inherited skin fragility disease dystrophic epidermolysis bullosa (DEB). Due to genetic defects in structural proteins, skin and mucous epithelia are prone to blistering and chronic wounding upon minor trauma. Furthermore, these wounds are commonly associated with excessive pruritus and predispose to the development of life-threatening squamous cell carcinomas, underscoring the unmet need for new therapeutic options to improve wound healing in this patient cohort. Vitamin D3 is acknowledged to play an important role in wound healing by modulating different cellular processes that impact epidermal homeostasis and immune responses. In this study, we evaluate the safety and efficacy of low-dose calcipotriol, a vitamin D3 analogue, in promoting wound healing and reducing itch and pain in patients with DEB.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Eligible DEB patients, aged\u2009\u2265\u20096\u00a0years and with a known mutation in the\n COL7A1<\/jats:italic>\n gene, were recruited to a placebo-controlled, randomized, double blind, cross-over phase II monocentric clinical trial. Patients were required to have at least two wounds with a minimum size of 6 cm\n 2<\/jats:sup>\n per wound. The primary objective was to evaluate efficacy of daily topical application of a 0.05\u00a0\u00b5g\/g calcipotriol ointment in reducing wound size within a 4-week treatment regimen. Secondary objectives were to assess safety, as well as the impact of treatment on pruritus, pain, and bacterial wound colonization in these patients.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Six patients completed the clinical trial and were included into the final analysis. Topical low-dose calcipotriol treatment led to a significant reduction in wound area at day 14 compared to placebo (88.4% vs. 65.5%,\n P<\/jats:italic>\n \u2009<\u20090.05). Patients also reported a significant reduction of pruritus with calcipotriol ointment compared to placebo over the entire course of the treatment as shown by itch scores of 3.16 vs 4.83 (\n P<\/jats:italic>\n \u2009<\u2009\n 0.05<\/jats:italic>\n ) and 1.83 vs 5.52 (\n P<\/jats:italic>\n \u2009<\u2009\n 0.0001<\/jats:italic>\n ) at days 14 and 28, respectively. Treatment with low-dose calcipotriol did not affect serum calcium levels and improved the species richness of the wound microbiome, albeit with no statistical significance.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our results show that topical treatment with low-dose calcipotriol can accelerate wound closure and significantly reduces itch, and can be considered a safe and readily-available option to improve local wound care in DEB patients.<\/jats:p>\n \n Trial<\/jats:italic>\n Registration<\/jats:italic>\n EudraCT: 2016\u2013001,967-35. Registered 28 June 2016,\n https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001967-35\/AT<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13023-021-02062-2","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T10:05:43Z","timestamp":1636365943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Christina","family":"Guttmann-Gruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Pi\u00f1\u00f3n Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Tockner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Klausegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolkersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khek-Chian","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Common","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Ude-Schoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Reichelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-0188","authenticated-orcid":false,"given":"Roland","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"2062_CR1","unstructured":"Bikle D. Vitamin D: Production, metabolism, and mechanisms of action. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth (MA) 2000."},{"issue":"4","key":"2062_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41574-019-0312-5","volume":"16","author":"D Bikle","year":"2020","unstructured":"Bikle D, Christakos S. New aspects of vitamin D metabolism and action - addressing the skin as source and target. Nat Rev Endocrinol. 2020;16(4):234\u201352.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2062_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1096\/fj.04-3284com","volume":"19","author":"AF Gombart","year":"2005","unstructured":"Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067\u201377.","journal-title":"FASEB J"},{"key":"2062_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jaut.2017.07.007","volume":"85","author":"F Colotta","year":"2017","unstructured":"Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun. 2017;85:78\u201397.","journal-title":"J Autoimmun"},{"issue":"1","key":"2062_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2340\/00015555-2781","volume":"98","author":"M Kim","year":"2018","unstructured":"Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, Murrell DF. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand. Acta Derm Venereol. 2018;98(1):70\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2062_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/bjd.18475","volume":"182","author":"A Reimer","year":"2020","unstructured":"Reimer A, Hess M, Schwieger-Briel A, Kiritsi D, Schauer F, Schumann H, et al. Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study. Br J Dermatol. 2020;182(6):1437\u201348.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2062_CR7","doi-asserted-by":"publisher","first-page":"13430","DOI":"10.1038\/s41598-018-31823-6","volume":"8","author":"C Guttmann-Gruber","year":"2018","unstructured":"Guttmann-Gruber C, Tockner B, Scharler C, Huttner C, Common JE, Tay ASL, et al. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes. Sci Rep. 2018;8(1):13430.","journal-title":"Sci Rep"},{"key":"2062_CR8","doi-asserted-by":"crossref","unstructured":"Robertson SJ, Orrin E, Lakhan MK, O'Sullivan G, Felton J, Robson A, et al. Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study. Acta Derm Venereol. 2021.","DOI":"10.2340\/00015555-3875"},{"issue":"1","key":"2062_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2062_CR10","doi-asserted-by":"publisher","first-page":"15064","DOI":"10.1038\/s41598-020-71794-1","volume":"10","author":"I Fuentes","year":"2020","unstructured":"Fuentes I, Guttmann-Gruber C, Tockner B, Diem A, Klausegger A, Cofre-Araneda G, et al. Cells from discarded dressings differentiate chronic from acute wounds in patients with Epidermolysis Bullosa. Sci Rep. 2020;10(1):15064.","journal-title":"Sci Rep"},{"key":"2062_CR11","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/ncomms6932","volume":"6","author":"E Hoste","year":"2015","unstructured":"Hoste E, Arwert EN, Lal R, South AP, Salas-Alanis JC, Murrell DF, et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun. 2015;6:5932.","journal-title":"Nat Commun"},{"key":"2062_CR12","doi-asserted-by":"crossref","unstructured":"Hoste E, Maueroder C, vanHove L, Catrysse L, Vikkula HK, Sze M, et al. Epithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation. Cell Rep. 2019;29(9):2689\u2013701 e4.","DOI":"10.1016\/j.celrep.2019.10.104"},{"issue":"1","key":"2062_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","volume":"16","author":"JY Tang","year":"2021","unstructured":"Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175.","journal-title":"Orphanet J Rare Dis"},{"key":"2062_CR14","doi-asserted-by":"crossref","unstructured":"Helde-Frankling M, Bjorkhem-Bergman L. Vitamin D in Pain Management. Int J Mol Sci. 2017;18(10).","DOI":"10.3390\/ijms18102170"},{"issue":"6","key":"2062_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/1346-8138.12102","volume":"40","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week. J Dermatol. 2013;40(6):424\u20137.","journal-title":"J Dermatol"},{"issue":"11","key":"2062_CR16","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jid.2017.07.002","volume":"137","author":"V Alexeev","year":"2017","unstructured":"Alexeev V, Salas-Alanis JC, Palisson F, Mukhtarzada L, Fortuna G, Uitto J, et al. Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration. J Invest Dermatol. 2017;137(11):2298\u2013308.","journal-title":"J Invest Dermatol"},{"key":"2062_CR17","doi-asserted-by":"crossref","unstructured":"Annicchiarico G, Morgese MG, Esposito S, Lopalco G, Lattarulo M, Tampoia M, et al. Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. Medicine (Baltimore). 2015;94(42):e1528.","DOI":"10.1097\/MD.0000000000001528"},{"issue":"2","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/jdv.12399","volume":"29","author":"T Lettner","year":"2015","unstructured":"Lettner T, Lang R, Bauer JW, Wally V. Increased levels of matrix metalloproteinase-9 and interleukin-8 in blister fluids of dystrophic and junctional epidermolysis bullosa patients. J Eur Acad Dermatol Venereol. 2015;29(2):396\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2062_CR19","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/jid.2015.243","volume":"135","author":"Y Umehara","year":"2015","unstructured":"Umehara Y, Kamata Y, Tominaga M, Niyonsaba F, Ogawa H, Takamori K. Cathelicidin LL-37 Induces Semaphorin 3A Expression in Human Epidermal Keratinocytes: Implications for Possible Application to Pruritus. J Invest Dermatol. 2015;135(11):2887\u201390.","journal-title":"J Invest Dermatol"},{"issue":"6098","key":"2062_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1126\/science.1225152","volume":"337","author":"S Naik","year":"2012","unstructured":"Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337(6098):1115\u20139.","journal-title":"Science"},{"issue":"11","key":"2062_CR21","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.jid.2018.04.026","volume":"138","author":"I Fuentes","year":"2018","unstructured":"Fuentes I, Guttmann-Gruber C, Tay ASL, Pinon Hofbauer J, Denil S, Reichelt J, et al. Reduced microbial diversity is a feature of recessive dystrophic epidermolysis bullosa-involved skin and wounds. J Invest Dermatol. 2018;138(11):2492\u20135.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"JD Fine","year":"2016","unstructured":"Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. JAMA Dermatol. 2016;152(11):1231\u20138.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2062_CR23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/bjd.12599","volume":"169","author":"G Petrof","year":"2013","unstructured":"Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, McGrath JA. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol. 2013;169(5):1025\u201333.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2062_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1742-481X.2012.01036.x","volume":"11","author":"P Al Ghazal","year":"2014","unstructured":"Al Ghazal P, Korber A, Klode J, Schmid EN, Buer J, Dissemond J. Evaluation of the Essen Rotary as a new technique for bacterial swabs: results of a prospective controlled clinical investigation in 50 patients with chronic leg ulcers. Int Wound J. 2014;11(1):44\u20139.","journal-title":"Int Wound J"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02062-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02062-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02062-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T10:09:58Z","timestamp":1636366198000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02062-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02062-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This placebo-controlled, randomized, double-blind, cross-over, phase II clinical trial (EudraCT: 2016\u2013001967-35) was approved by the ethics committee of Salzburg (415-E\/2043\/7\u20132016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients or their legal guardians gave written informed consent for publication of the data generated in this trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"473"}}